Forbes August 14, 2024
A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology offers hope for millions. RNA interference gene therapies can potentially reduce the need for daily medications to just one or two injections per year. One such therapy, inclisiran, a small interfering RNA (siRNA) medication, has demonstrated promise in clinical trials.
A study published in the New England Journal of Medicine demonstrated that Inclisiran can dramatically lower LDL cholesterol levels in patients with atherosclerotic cardiovascular disease. This could redefine treatment protocols for millions of people struggling with high cholesterol.
Introducing Inclisiran
The New England Journal of Medicine study aimed to assess the effectiveness and...
Today's Sponsors
Today's Sponsor